News

CHPA names new VP finance and administration, CFO

BY Michael Johnsen

WASHINGTON — The Consumer Healthcare Products Association on Monday announced that Lisa Murphy Early will join the association as VP finance and administration and CFO. 

“Lisa is a highly experienced association executive with extensive financial, managerial and strategic planning experience in the non-profit and for-profit sectors,” stated CHPA president and CEO Scott Melville. 

Early will be director of CHPA’s finance management, human resources, information technology, meetings and administration functions. She will also serve as a member of the association’s senior management team.

A graduate of Michigan State University, Early is a certified public accountant who previously served as CFO and SVP, finance & administration for the Biotechnology Industry Organization. In that role, she oversaw all finance and administrative operations, which included finance, accounting, human resources, information technology and office facilities.

“Lisa played a key role in growing BIO from a small niche association to one of Washington D.C.’s most influential industry associations,” Melville noted. “That experience will be incredibly valuable as we look to strengthen and expand CHPA’s capabilities on behalf of its members.”

Earlier in her career, Early held a variety of accounting and financial positions at several biotechnology and communications companies including director of accounting for American Mobile Satellite Corporation, a publicly traded telecommunications firm, and controller for OncorMed, a publicly traded biotechnology company.


Are you a nurse practitioner or physician’s assistant? Join our Facebook group to get all the latest news dedicated to delivering healthcare services to patients in retail pharmacy clinics.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

News

Boulder Brands acquires majority stake in manufacturer of diabetes management products

BY Jason Owen

BOULDER, Colo. — Boulder Brands, Inc. announced last week it  had acquired 80% of GlucoBrands, LLC, owner of Level Life Foods. Based in Colorado, Level is a growing company, approaching $1 million in sales, which provides products to help in the daily management of diabetes.

Level’s first products, Level Life Glucose Gels, were launched in September of 2012 for use primarily by EMTs and Type 1 diabetics to help correct low blood-sugar level events. With the acquisition, Boulder Brands will launch Level’s next line of products of bars and shakes designed to help control carbohydrates, support healthy blood-sugar levels and help satisfy hunger for those managing carbohydrate and sugar intake, including consumers who may be pre-diabetic or who already have Type 2 diabetes.

Health organizations rank diabetes as a top health concern as there are currently 26 million people living with diabetes, and 80 million people with pre-diabetes, in the United States today. Level is positioned to harness the need for better nutrition solutions for the diabetes epidemic by creating a lifestyle brand that provides consumers with products that contain a healthier level of carbohydrates and a good source of protein and fiber.

“We are excited to add Level to our health and wellness innovation platform as it will become our fourth category-elastic, need-state vertical brand, serving the diabetic consumer. Ultimately, Level will complement Smart Balance in heart-health, Earth Balance in plant-based and Udi’s and Glutino in gluten-free. Diabetes is one of the largest and fastest growing need states in consumer foods today. However, it is an underserved market with few brands offering great tasting products with the optimal balance of sugar and carbohydrates. Level is market-ready and is currently launching four bars and four shakes. As with our other brands, category expansion opportunities are extensive, and we look forward to growing Level to a much larger brand in the future,” said Steve Hughes, chairman and chief executive of Boulder Brands.”


Are you a nurse practitioner or physician’s assistant? Join our Facebook group to get all the latest news dedicated to delivering healthcare services to patients in retail pharmacy clinics.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

News

Actavis’ generic version of Opana ER wins FDA approval

BY Alaric DeArment

PARSIPPANY, N.J. — The Food and Drug Administration has approved a generic opioid painkiller made by Actavis, the drug maker said.

Actavis announced the approval of oxymorphone hydrochloride extended-release tablets in the 5-mg, 10-mg, 20-mg, 30-mg and 40-mg strengths. The drug is a generic of Endo Health Solutions’ Opana ER, but is based on a non-crush resistant version that was withdrawn from the market last year. An FDA rule finalized earlier this year allows for generic versions of the earlier formulation of Opana ER, though Endo only makes the crush-resistant formulation.

Opana ER tablets had sales of about $461 million during the 12-month period that ended in May, according to IMS Health. Actavis already markets the 7.5-mg and 15-mg versions.

 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES